Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Essa Pharma (EPIX)

Essa Pharma (EPIX)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
1.7700 +0.1400 (+8.59%) 04/16/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 1.7500 -0.0200 (-1.13%) 19:56 ET
Quote Overview for Wed, Apr 16th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
1.7000
Day High
1.8750
Open 1.8000
Previous Close 1.6300 1.6300
Volume 907,400 907,400
Avg Vol 178,380 178,380
Stochastic %K 78.59% 78.59%
Weighted Alpha -16.58 -16.58
5-Day Change +0.2500 (+16.45%) +0.2500 (+16.45%)
52-Week Range 1.4000 - 7.8800 1.4000 - 7.8800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,354
  • Shares Outstanding, K 44,389
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,540 K
  • EBIT $ -37 M
  • EBITDA $ -36 M
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.62

Options Overview Details

View History
  • Implied Volatility 166.74% ( -116.14%)
  • Historical Volatility 40.45%
  • IV Percentile 52%
  • IV Rank 24.27%
  • IV High 605.09% on 01/22/25
  • IV Low 26.26% on 06/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 312
  • Volume Avg (30-Day) 119
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,908
  • Open Int (30-Day) 2,301

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.19
  • Number of Estimates 1
  • High Estimate -0.19
  • Low Estimate -0.19
  • Prior Year -0.20
  • Growth Rate Est. (year over year) +5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4200 +24.65%
on 04/09/25
Period Open: 1.6200
1.8750 -5.60%
on 04/16/25
+0.1500 (+9.26%)
since 03/14/25
3-Month
1.4200 +24.65%
on 04/09/25
Period Open: 1.7500
1.8750 -5.60%
on 04/16/25
+0.0200 (+1.14%)
since 01/16/25
52-Week
1.4000 +26.43%
on 11/01/24
Period Open: 7.4300
7.8800 -77.54%
on 09/16/24
-5.6600 (-76.18%)
since 04/16/24

Most Recent Stories

More News
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and...

EPIX : 1.7700 (+8.59%)
ESSA Pharma: Fiscal Q1 Earnings Snapshot

ESSA Pharma: Fiscal Q1 Earnings Snapshot

EPIX : 1.7700 (+8.59%)
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and...

EPIX : 1.7700 (+8.59%)
ESSA Pharma: Fiscal Q4 Earnings Snapshot

ESSA Pharma: Fiscal Q4 Earnings Snapshot

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company that, prior to the discontinuation of its clinical...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment...

EPIX : 1.7700 (+8.59%)
ESSA Pharma: Fiscal Q3 Earnings Snapshot

ESSA Pharma: Fiscal Q3 Earnings Snapshot

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the JonesHealthcare Seaside Summit

/CNW/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the Jefferies Global Healthcare Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

/CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2 dose...

EPIX : 1.7700 (+8.59%)
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023

/CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company, focused on developing novel therapies for the...

EPIX : 1.7700 (+8.59%)
U.S. CPI, Fed Decision in News Next Wee

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q2) Reported EPS for $1.05, ...

PFX : 51.09 (+0.01%)
ORCL : 129.76 (-3.12%)
DOL.TO : 169.59 (+0.72%)
JCI : 76.66 (-2.46%)
COST : 967.75 (-0.94%)
BLBD : 33.25 (-1.34%)
TCL-A.TO : 17.46 (-0.06%)
LEN : 102.76 (-2.21%)
NDSN : 180.69 (-1.31%)
PLAB : 17.78 (-1.17%)
ADBE : 344.19 (-1.77%)
MANU : 13.80 (-1.78%)

Business Summary

ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada.

See More

Key Turning Points

3rd Resistance Point 2.0383
2nd Resistance Point 1.9567
1st Resistance Point 1.8633
Last Price 1.7700
1st Support Level 1.6883
2nd Support Level 1.6067
3rd Support Level 1.5133

See More

52-Week High 7.8800
Fibonacci 61.8% 5.4046
Fibonacci 50% 4.6400
Fibonacci 38.2% 3.8754
Last Price 1.7700
52-Week Low 1.4000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro